Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro in vivo correlations

Clinical Pharmacokinetics

Volumn 36, Issue 3, 1999, Pages 211-231

  Lavé, Thierry ^a   Coassolo, Philippe ^a   Reigner, Bruno ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOBARBITAL; AMSACRINE; ASULACRINE ISETHIONATE; BOSENTAN; CAFFEINE; CHLORPROMAZINE; CIMETIDINE; CYCLOSPORIN; DIAZEPAM; ERYTHROMYCIN; HEXOBARBITAL; MIBEFRADIL; MIDAZOLAM; MOFAROTENE; PENTAZOCINE; PENTOBARBITAL; PHENAZONE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PROPRANOLOL; QUINIDINE; RO 246173; TEBUFELONE; THEOPHYLLINE; TOLBUTAMIDE; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ALLOMETRY; AREA UNDER THE CURVE; DOSE CALCULATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; LIVER CLEARANCE; LIVER METABOLISM; PREDICTION; PRIORITY JOURNAL; REVIEW; TECHNIQUE;

EID: 0032921527     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936030-00003     Document Type: Review

References (63)

1. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned companies (1964-1985). Br J Clin Pharmacol 1988; 25: 387-96
2. Boxenbaum H, Dilca C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995; 35: 957-66
3. Bonati M, Latini R, Tognoni G, et al. Interspecies comparison of in vivo caffeine pharmacokinetics in human, monkey, rabbit, rat and mouse. Drug Metab Rev 1984; 15: 1355-83
4. Brocks DR, Freed MI, Martin DE, et al. Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharm Res 1996; 13: 794-7
5. Campbell DB. Can allometric interspecies scaling be used to predict human kinetics. Drug Inf J 1994; 28: 235-45
6. Gascon AR, Calvo B, Hernandez RM, et al. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. Pharm Res 1994; 11 (7): 945-50
7. Ibrahim SS, Boudinot FD. Pharmacokinetics of 2',3'-dideoxycytidine in rats: application to interspecies scale-up. J Pharm Pharmacol 1989; 41: 829-34
8. Ings RM. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 20: 1201-31
9. Khor SP, Amyx H, Davis ST, et al. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: alIometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. Cancer Chemother Pharmacol 1997; 39: 233-8
10. Lapka R, Rejholec V, Sechser T, et al. Interspecies pharmacokinetic scaling of metazosin, a novel alpha-adrenergic antagonist. Biopharm Drug Dispos 1989; 10: 581-9
11. Lave T, Levettrafit B, Schmitthoffmann AH, et al. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 1995; 84: 1285-90
12. Lave T, Saner A, Coassolo P, et al. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 1996; 48: 573-7
13. Lave T, Coassolo P, Ubeaud G, et al. Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharm Res 1996; 13: 97-101
14. Lave T, Dupin S, Schmitt M, et al. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT): use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 1996; 26: 839-51
15. McNamara PJ. Interspecies scaling in pharmacokinetics. In: Welling PG, Tse FLS, Dighe SV, editors. Pharmaceutical bioequivalence. New York: Marcel Dekker, 1991: 267-300
16. Mordenti J. Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrob Agents Chemother 1985; 27: 887-91
17. Mordenti J. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 1985; 74: 1097-9
18. Mordenti J, Chen SA, Moore JA, et al. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8: 1351-9
19. Mordenti J. Osaka G, Garcia K, et al. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136: 75-8
20. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58
21. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-79
22. Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 1977; 200: 420-4
23. Rodriguez AD. Preclinical drug metabolism in the age of high throughput screening: an industrial perspective. Pharm Res 1997; 14: 1504-10
24. Lave T. Dupin S, Schmitt C, et al. The use ofhuman hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 1997; 14: 152-5
25. Reigner BG, Williams PEO, Patel JH, et al. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development: experience within Hoffmann La Roche. Clin Pharmacokinet 1997; 33: 142-52
26. Rahmani R, Richard B, Fabre G, et al. Extrapolation of preclinical pharmacokinetic data to therapeutic drug use. Xenobiotica 1988; 1: 71-88
27. Carlile DJ, Zomorodi K, Houston JB. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos 1997; 25: 903-11
28. Ubeaud G, Schmitt C, Jaeck D, et al. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 1995; 25: 1381-90
29. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47
30. Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 147-71
31. Hoener BA. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm Drug Dispos 1994; 15: 295-304
32. Bäärnhielm C, Dählback H. Skanberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharm Toxicol 1986; 59: 113-22
33. Juergens KD. Allometry as a tool for extrapolation of biological variables. Comp Biochem Physiol 1991; 100C: 287-90
34. Adolph EF. Quantitative relations in the physiological contributions of mammals. Science 1949; 109: 579-85
35. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75: 1028-40
36. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-32
37. Weiss M, Sziegoleit W, Forster W. Dependence of pharmacokinetic parameters on the body weight. Int J Clin Pharmacol 1977; 15: 572-5
38. Boxenbaum B, D'Souza RW. Interspecies pharmacokinetic scaling, biological design and neoteny. In: Testa B, editor. Advances in drug research. London: Academic Press Limited, 1990: 139-96
39. Boxenbaurn H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071-121
40. Boxenbaurn H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 1984; 9: 177-83
41. Yates FE, Kugler PN. Similarity principles and intrinsic geometries: contrasting approaches to interspecies scaling. J Pharm Sci 1986; 75: 1019-27
42. Sacher GA. Relation of lifespan to brain weight and body weight in mammals. In: Wolstenholme G, O'Connor M, editors. The lifespan of animals. Boston: Little Brown & Co., 1959: 115-41
43. Lave T, Schmitt-Hoffmann AH, Coassolo P, et al. A new extrapolation method from animal to man: application to a metabolized compound, mofarotene. Life Sci 1995; 56: 473-8
44. Mahmood I, Balian ID. Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica 1996; 26: 887-95
45. Lave T, Dupin S, Schmitt C, et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 584-90
46. Boxenbaum M. Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 1982; 10: 411-26
47. Sawada Y, Hanano M, Sugiyama Y, et al. Prediction of the disposition of nine weakly acidic and six basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 1985; 13: 477-92
48. Bachmann K, Pardoe D, White D. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 1996; 104: 400-7
49. Chiou WL, Choi YM. Unbound total (plasma) clearance approach in interspecies pharmacokinetics correlation: theophylline-cimetidine interaction. Pharm Res 1995; 12: 1238-9
50. Cruze CA, Kelm GR, Meredith MP. Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharmaceut Res 1995; 12: 895-901
51. Patel BA, Boudinot FD, Schinazi RF, et al. Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. J Pharmacobiodyn 1990; 13: 206-11
52. Hutchaleelaha A, Chow HH, Mayersohn M. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 1997; 49: 178-83
53. Elder CA, Modi MW. Interspecics scaling of a thienodiazepine platelet-activating factor receptor antagonist. Drug Metab Dispos 1995; 23: 776-8
54. Van Hoogdalem EJ, Socishi Y, Matsushima H, et al. Disposition of the selective alpha I A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997; 86: 1156-61
55. Izumi T, Enomoto S, Hosiyama K, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996; 277: 1630-41
56. Mahmood I, Balian JD. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85: 411-4
57. Owens SM, Hardwick WC, Blackall D. Phencyclidine pharmacokinetic scaling among species. J Pharmacol Exp Ther 1987; 242: 96-101
58. Paxton JW, Kim SN, Whitfield I.R. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res 1990; 50: 2692-7
59. Ritschel WA, Vachharajani NN, Johnson RD, et al. Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species. Methods Find Exp Clin Pharmacol 1991; 13: 697-702
60. Sanwald-Ducray P, Dow J. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 1997; 27: 189-201
61. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 23: 1008-21
62. Laakso T, Artursson P, Sjoholm I. Biodegradable microspheres. IV: factors affecting the distribution and degradation of polyacryl starch microparticles. J Pharm Sci 1986; 75: 962-7
63. Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 1996; 17: 273-310